公开(公告)号：EP1447095A4

公开(公告)日：2009-08-05

申请号：EP02779986

申请日：2002-11-01

申请人： EGASHIRA KENSUKE

发明人： EGASHIRA KENSUKE ,  TAKESHITA AKIRA ,  SATA MASATAKA

IPC分类号： A61K31/00 ,  A61K38/00 ,  A61P9/10 ,  A61P37/06 ,  C07K14/52 ,  A61K45/00 ,  A61K39/395 ,  A61K48/00

CPC分类号： C07K14/523 ,  A61K31/00 ,  A61K38/00

摘要： Preventives and/or remedies for post-transplant arteriosclerosis as a rejection of organ transplant or endosporium thickening after self-homogeneous arteriovenous graft transplant which contain a monocyte chemotactic protein-1 MCP-1 inhibitor as the active ingredient. Administration of the MCP-1 inhibitor makes it possible to prevent or treat post-transplant arteriosclerosis as a rejection of organ transplant and endosporium thickening after self-homogeneous arteriovenous graft transplant.

公开(公告)号：EP1726318A1

公开(公告)日：2006-11-29

申请号：EP05721433.0

申请日：2005-03-17

申请人： Egashira, Kensuke

发明人： Egashira, Kensuke

IPC分类号： A61L27/00 ,  A61K38/00 ,  A61K38/16 ,  A61K38/22 ,  A61K47/48 ,  A61K48/00 ,  A61P9/00 ,  A61P9/10

CPC分类号： A61L31/16 ,  A61K38/39 ,  A61K47/6957 ,  A61L31/10 ,  A61L2300/258 ,  A61L2300/62 ,  A61K2300/00

摘要： The present invention provides a more safe and highly effective stent having functions such as anti-inflammatory action, antithrombotic action, maintenance of tissue restoration response and maintenance of endothelial regeneration. More speciffically, the drug/gene eluting stent has a layer containing a gene encoding a hybrid polypeptide on the surface. The hybrid polypeptide is preferably a bound of fibronectin-derived collagen binding domain (FNCBD) polypeptide and an anti-inflammatory factor or an angiogenic factor. The uniform fine particle size capsules can directly deliver the gene encoding the hybrid polypeptide to the lesion and have benefits of reducing the given doses, and thus improving safety and efficacy and further maintaining the efficacy for a long period.

摘要翻译： 本发明提供了具有诸如抗炎作用，抗血栓形成作用，维持组织恢复反应和维持内皮再生功能的更安全和高效的支架。 更特别地，药物/基因洗脱支架具有含有编码表面杂交多肽的基因的层。 杂合多肽优选是纤连蛋白衍生的胶原结合结构域（FNCBD）多肽和抗炎因子或血管生成因子的结合。 均匀的细粒度胶囊可以将编码杂合多肽的基因直接递送到病变，并且具有减少给定剂量的益处，从而提高安全性和功效，并进一步长时间保持功效。

公开(公告)号：EP1447095B1

公开(公告)日：2012-06-13

申请号：EP02779986.5

申请日：2002-11-01

申请人： Egashira, Kensuke

发明人： EGASHIRA, Kensuke ,  TAKESHITA, Akira ,  SATA, Masataka

IPC分类号： A61K45/00 ,  A61K38/00 ,  A61K39/395 ,  A61K48/00 ,  A61P9/10 ,  A61P37/06

CPC分类号： C07K14/523 ,  A61K31/00 ,  A61K38/00

摘要： Preventives and/or remedies for post-transplant arteriosclerosis as a rejection of organ transplant or endosporium thickening after self-homogeneous arteriovenous graft transplant which contain a monocyte chemotactic protein-1 (MCP-1) inhibitor as the active ingredient. Administration of the MCP-1 inhibitor makes it possible to prevent or treat post-transplant arteriosclerosis as a rejection of organ transplant and endosporium thickening after self-homogeneous arteriovenous graft transplant.

公开(公告)号：EP1325751A4

公开(公告)日：2005-05-04

申请号：EP01972593

申请日：2001-09-28

申请人： DAIICHI SEIYAKU CO ,  EGASHIRA KENSUKE

发明人： EGASHIRA KENSUKE ,  TAKESHITA AKIRA ,  KOYANAGI MASAMICHI ,  NAKAMUTA MAKOTO ,  NISHIDA KENICHI

IPC分类号： A61K38/19 ,  A61K48/00 ,  A61P1/16 ,  A61P43/00 ,  A61K45/00

CPC分类号： A61K38/195 ,  A61K48/00

摘要： Preventives and/or remedies for liver diseases containing as the active ingredient monocyte chemoattractant protein-1 (MCP-1) function inhibitors. Administration of the MCP-1 function inhibitors exerts effects of preventing and/or treating liver diseases.

公开(公告)号：EP1447095A1

公开(公告)日：2004-08-18

申请号：EP02779986.5

申请日：2002-11-01

申请人： Egashira, Kensuke

发明人： EGASHIRA, Kensuke ,  TAKESHITA, Akira ,  SATA, Masataka

IPC分类号： A61K45/00 ,  A61K38/00 ,  A61K39/395 ,  A61K48/00 ,  A61P9/10 ,  A61P37/06

CPC分类号： C07K14/523 ,  A61K31/00 ,  A61K38/00

摘要： A preventive and/or therapeutic agent for post-transplant arteriosclerosis occurring as a rejection response to organ transplantation or for auto- or allo-arteriovenous graft post-transplant intimal thickening, wherein the agent contains, as an active ingredient, a monocyte chemoattractant protein-1 (MCP-1) function inhibitor.
Administration of the MCP-1 function inhibitor enables prevention and treatment of post-transplant arteriosclerosis occurring as a rejection response to organ transplantation or for auto- or allo-arteriovenous graft post-transplant intimal thickening.

摘要翻译： 对移植后动脉硬化症的预防和/或治疗剂发生的作为拒绝响应于器官移植或自体或异体动静脉移植物移植后的内膜增厚，worin该试剂含有，作为活性成分，单核细胞趋化蛋白 1（MCP-1）的功能抑制剂。 的MCP-1功能抑制剂给药允许预防和治疗移植后动脉硬化发生的作为拒绝响应于器官移植或自体或异体动静脉移植物移植后的内膜增厚。